0000000000319700

AUTHOR

Fagiuoli S

showing 8 related works from this author

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib

2011

Sorafenib (Nexavar®, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function. This drug is now recommended in patients with advanced hepatocellular carcinoma as first-line therapy and for patients not suitable for locoregional treatment. This brief article, produced by a multidisciplinary panel including specialists in gastroenterology and oncology, provides an overview of the major issues related to systemic treatment of hepatocellular carcinoma with sorafenib, including staging and prognostic strategies, assessmen…

OncologySorafenibLiver CirrhosisNiacinamidemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.drug_classPyridinesAntineoplastic AgentsGastroenterologyTyrosine-kinase inhibitorsystemic therapyliver cancerLiver diseaseInternal medicinemedicineHumansPharmacology (medical)treatmentbusiness.industryPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsDisease Managementhepatocellular carcinomamedicine.diseasehepatocellular carcinoma sorafenb cirrhosisdigestive system diseasesOncologyTolerabilityHepatocellular carcinomasorafenibLiver functionLiver cancerbusinessmanagementmedicine.drugcirrhosi
researchProduct

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

2007

The effect of achieving a sustained virological response (SVR) following interferon-α (IFNα) treatment on the clinical outcomes of patients with HCV-related cirrhosis is unknown. In an attempt to assess the risk of liver-related complications, HCC and liver-related mortality in patients with cirrhosis according to the response to IFNα treatment, a retrospective database was developed including all consecutive patients with HCV-related, histologically proven cirrhosis treated with IFNα monotherapy between January 1992 and December 1997. SVR was an undetectable serum HCV-RNA by PCR 24 weeks after IFNα discontinuation. HCC was assessed by ultrasound every 6 months. Independent predictors of al…

Liver CirrhosisMaleANTIVIRAL TREATMENTMultivariate analysisCirrhosisHepacivirusdrug therapy/mortality/virologyGastroenterologyCohort StudiesINTERFERON; HEPATITIS C; CIRRHOSIS; CHRONIC HEPATITIS C; ANTIVIRAL TREATMENT; SUSTAINED VIROLOGICAL RESPONSE; Liver cirrhosis.MedicinegeneticsLongitudinal StudiesViralCIRRHOSISHazard ratiovirus diseasesHepatitis CAdult Antiviral Agents; therapeutic use Cohort Studies Female Hepacivirus; genetics Hepatitis C; blood/complications/drug therapy/mortality Humans Interferon-alpha; therapeutic use Liver Cirrhosis; drug therapy/mortality/virology Longitudinal Studies Male Middle Aged Multivariate Analysis RNA; Viral; blood Retrospective Studies Survival Analysis Treatment OutcomeMiddle AgedLiver cirrhosis.Treatment OutcomeSUSTAINED VIROLOGICAL RESPONSEHEPATITIS CLiver Cirrhosis/drug therapy Liver Cirrhosis/virologyRNA ViralFemaleAdultINTERFERONmedicine.medical_specialtyCHRONIC HEPATITIS CAntiviral AgentsbloodInternal medicineHumansRetrospective StudiesSustained virological response interferon-alpha HCV-related cirrhosis:Hepatologybusiness.industryProportional hazards modelInterferon-alphaRetrospective cohort studyblood/complications/drug therapy/mortalityHepatologymedicine.diseaseSurvival Analysisdigestive system diseasesDiscontinuationSurgerytherapeutic useMultivariate AnalysisRNAbusiness
researchProduct

A multicenter Italian Study of rescue adefovir dipivoxil tehrapy in lamivudine resistant patients: a 2-year anlysis of 604 patients.

2005

researchProduct

A muticenter Italian Study od rescue adefovir dipivoxil therapy in lamivudine resistant patients: a 2 years analysis of 650 pATIENTS.

2006

researchProduct

Adefovir and Lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatit…

2006

researchProduct

Management of infections pre- and post-liver transplantation: Report of an AISF consensus conference

2014

SummaryThe burden of infectious diseases both before and after liver transplantation is clearly attributable to the dysfunction of defensive mechanisms of the host, both as a result of cirrhosis, as well as the use of immunosuppressive agents.The present document represents the recommendations of an expert panel commended by the Italian Association for the Study of the Liver (AISF), on the prevention and management of infectious complications excluding hepatitis B, D, C, and HIV in the setting of liver transplantation.Due to a decreased response to vaccinations in cirrhosis as well as within the first six months after transplantation, the best timing for immunization is likely before transp…

Liver Cirrhosismedicine.medical_specialtyCirrhosismedicine.medical_treatmentLiver transplantationInfectionsInvasive fungal infectionPostoperative ComplicationsBacterial infectionsInvasive fungal infectionsTransplantation ImmunologyLower respiratory tract infectionHumansMedicineSmallpoxVoluntary Health AgenciesIntensive care medicineImmunosuppression TherapyViral infectionsInfection ControlCirrhosiLiver transplantationAttenuated vaccineHepatologybusiness.industryVaccinationHepatitis Bmedicine.diseaseVaccinationTransplantationBacterial infections; Cirrhosis; Invasive fungal infections; Liver transplantation; Viral infections; Humans; Immunosuppression; Infection; Infection Control; Italy; Liver Cirrhosis; Liver Transplantation; Postoperative Complications; Transplantation Immunology; Vaccination; Voluntary Health Agencies; HepatologyCirrhosisItalyViral infectionBacterial infections; Cirrhosis; Invasive fungal infections; Liver transplantation; Viral infectionsAISFImmunologyBacterial infectionInfectionbusinessImmunosuppression
researchProduct

The Italian experience on paediatric liver transplantation: 1988-1999 report

2002

Abstract Background. Liver transplantation is the treatment of choice for end-stage liver disease in both adult and paediatric patients. The Italian experience in paediatric liver transplantation during the period 1988–1999 is reported herein. Patients and methods. This report concerns 228 liver transplantations performed in 207 patients (100 male, 107 female, mean age 5.1±4.4 years) in 11 Italian centres. The mean waiting time on the transplantation list was 6. 1±8.9 months and the main indications for the procedure were biliary atresia, inborn metabolic disorders, liver cirrhosis, liver neoplasms, Alagille syndrome, and fulminant hepatic failure. Results. The cumulative survival rate was …

medicine.medical_specialtyPediatricsCirrhosisLiver transplantationHepatologybusiness.industrymedicine.medical_treatmentGastroenterologyLiver transplantationmedicine.diseaseSurgeryTransplantationLiver diseaseFulminant hepatic failureSurvival analysiBiliary atresiaAlagille syndromePaediatric ageMedicinebusinessSurvival rate
researchProduct

Liver transplantation: the Italian experience

2002

Abstract Background. Liver transplantation is the standard treatment for patients with end-stage liver disease no longer responsive to conventional medical treatment Aims . To report the longterm experience of liver transplantation in Italy. Patients and Methods . Data were obtained retrospective by means of a multiple-item form collected from 15 Italian liver transplant centres. The filing centre was centralized. Results . A total of 3323 liver transplants were performed on 3026 patients, with a cumulative proportional survival of 72.4%. Three, 5 and 10 years' patient survival rates were 72.3%, 68.8% and 61.3%, respectively. The most common indication for liver transplantation were hepatit…

AdultGraft RejectionMalemedicine.medical_specialtyAlcoholic liver diseaseCirrhosisAdolescentmedicine.medical_treatmentLiver transplantationGastroenterologyLiver diseaseRecurrenceInternal medicinePrevalenceMedicineHumansAgedRetrospective StudiesLiver transplantationHepatologybusiness.industryLiver DiseasesPatient SelectionGastroenterologyHepatitis CHepatitis BMiddle Agedmedicine.diseaseTransplantationSurvival RateItalyFemaleHepatitis D virusbusinessLiver disease
researchProduct